米国企業
Zivo Bioscience, Inc.

Zivo Bioscience, Inc.ZIVO

時価総額

$2001.5万

PER

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日
Cash	225,696	47,147	493,103	1,383	506,986	317,135	388,891	346,111	137,862	9	2
Prepaid expenses	-	-	-	-	-	15,143	-	23,282	29,953	58,078	102,416
Total current assets	249,830	90,805	688,527	33,107	520,423	332,278	-	369,393	167,815	9	2
PROPERTY AND EQUIPMENT, NET	83,546	13,203	93,750	68,750	18,750	-	-	-	-	-	-
Operating lease - right of use asset	-	-	-	-	-	-	-	-	49,364	27,225	189,282
Security deposit	-	-	-	-	-	-	-	-	-	3,000	32,058
Total other assets	130,118	-	1,392,126	68,750	-	-	-	-	-	30,225	221,340
TOTAL ASSETS	463,494	234,004	2,174,403	101,857	737,292	4,210,079	-	369,393	220,179	9	2
Accounts payable	660,565	938,640	483,208	1,225,589	666,365	541,710	-	1,372,428	1,559,627	654,333	490,670
Current portion of long-term operating lease	-	-	-	-	-	-	-	-	29,172	15,178	99,259
Convertible debentures payable	-	-	-	-	-	-	-	-	-	240,000	240,000
Deferred R&D obligations - participation agreements	-	-	-	-	-	-	-	-	1,936,800	1	525,904
Deferred R&D obligations - participation agreements related parties	-	-	-	-	-	-	-	-	-	369,037	175,427
Accrued interest	-	-	-	-	2,659,574	1,649,240	-	1,952,606	2,464,724	95,886	98,286
Accrued liabilities - payroll and directors fees	75,349	270,682	738,686	1,238,994	-	10,000	-	102,500	214,250	-	398,176
Total current liabilities	1,788,336	3,361,287	10,877,452	6,233,983	11,182,480	4,560,803	-	8,707,876	11,393,915	3	2
Long-term operating lease, net of current portion	-	-	-	-	-	-	-	-	15,178	-	105,919
Total long-term liabilities	706,657	828,908	890,811	237,042	3,176,047	15,953,768	-	-	136,878	-	105,919
TOTAL LIABILITIES	2,494,993	4,190,195	11,768,263	6,471,025	14,358,527	20,514,571	-	8,707,876	11,530,793	3	2
Common stock, $0.001 par value, 150,000,000 and 150,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 9,419,660 and 9,419,660 issued and outstanding at December 31, 2022, and December 31, 2021, respectively	100,036	105,318	116,852	128,774	136,745	141,107	-	396,737	413,036	9,420	9,420
Additional paid-in capital	27,130,276	28,448,705	32,895,380	35,427,339	40,016,059	47,366,814	-	81,222,726	87,340,025	114	116
Accumulated deficit	-29,261,809	-32,510,214	-42,606,092	-41,925,281	-53,774,039	-63,812,413	-	-89,957,946	-99,063,675	-108,227,041	-115,804,530
Total stockholders' equity (deficit)	-2,031,497	-3,956,191	-9,593,860	-6,369,168	-13,621,235	-16,304,492	-	-8,338,483	-11,310,614	6	-10,622
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	463,494	234,004	2,174,403	101,857	737,292	4,210,079	-	369,393	220,179	9	2